Sage Therapeutics, Inc.
—- Market cap
- —
- Debt
- —
- Cash
- −$81.02M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: SAGE stock price vs WHR: inconclusive — current versus $0.10 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WHR's multiple
Implied fair value · at SAGE's multiple
Needs SAGE P/S.
Snapshot Sep 9, 2026, 2:21 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 27% equity / 73% debt · EV / Revenue 0.53x · EV proxy / EBITDA proxy 7.01x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Sage Therapeutics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
WHIRLPOOL CORP /DE/ · implied price per share
Bear
-$46.25
Base
-$39.05
Bull
-$26.28
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BIOGEN INC.
SAGE vs BIIB
ELI LILLY & Co
SAGE vs LLY
SUPERNUS PHARMACEUTICALS, INC.
SAGE vs SUPN
Harmony Biosciences Holdings, Inc.
SAGE vs HRMY
BEST BUY CO INC
SAGE vs BBY
HOME DEPOT, INC.
SAGE vs HD
GENERAL ELECTRIC CO
SAGE vs GE
HELEN OF TROY LTD
SAGE vs HELE
NEWELL BRANDS INC.
SAGE vs NWL
Spectrum Brands Holdings, Inc.
SAGE vs SPB
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.